In terms of time-to-event analyses, our findings were comparable with those of previous studies that had evaluated the treatment of early or operable HER2-positive breast cancer with trastuzumab administered in both the neoadjuvant and adjuvant settings. The gene discussed is ERBB2; the disease is breast carcinoma.